Biotech Values

[DewDiligence]

Peculiar statement on Tofacitinib pricing:

http://www.reuters.com/article/2011/05/26/pfizer-arthritis-price-idUSLDE74O27Q20110526

Georg Schett, head of rheumatology and immunology at the University of Erlangen-Nuremberg, believes tofacitinib should be priced between biological anti-TNFs, costing up to $20,000 a year, and the around $1,000 older drug methotrexate.

LOL—he’s not exactly going out on a limb.